Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Buy” by Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have earned an average recommendation of “Buy” from the six research firms that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $25.60.

ATXS has been the topic of a number of recent research reports. Oppenheimer boosted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, December 10th.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $7.45 on Monday. The business’s 50-day simple moving average is $9.85 and its 200 day simple moving average is $10.70. The company has a market cap of $420.43 million, a P/E ratio of -3.56 and a beta of 0.70. Astria Therapeutics has a one year low of $6.91 and a one year high of $16.90.

Institutional Trading of Astria Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC increased its position in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the last quarter. PDT Partners LLC acquired a new position in Astria Therapeutics in the third quarter worth about $140,000. SG Americas Securities LLC bought a new stake in Astria Therapeutics in the third quarter valued at about $155,000. Hsbc Holdings PLC acquired a new stake in Astria Therapeutics during the second quarter valued at approximately $171,000. Finally, Intech Investment Management LLC bought a new position in Astria Therapeutics during the 3rd quarter worth approximately $228,000. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.